
EFSA’s current review of fluazinam should also answer why an old industry study was, according to two researchers, absent from the European approval record in 2008 and why their later warning did not lead to a new analysis sooner. That is the concrete oversight issue raised by DN’s new reporting, rather than a settled finding of harm or a ban.
Fluazinam is used against fungal disease in Swedish and European potato fields. Axel Mie and Christina Rudén of Stockholm University told DN that they examined an industry-commissioned study from about 20 years ago for ISK Biosciences, which sells the substance. They say the company had not submitted the study to European authorities before the 2008 approval.
Mie also says he alerted European authorities to the issue three years ago. According to DN, he learned only in April 2026 that no new analysis had been carried out. EFSA declined an interview but wrote to the newspaper that an evaluation of fluazinam is under way and that information from ISK Biosciences is being reviewed again.
That timeline warrants a more specific public account from regulators. An authority need not immediately adopt a researcher’s interpretation. But when the warning concerns an identified study and its place in an approval dossier, it should be able to explain which documents it received, how it assessed the objection and why any fresh analysis took time.
The researchers also argue that their recalculation found adverse brain effects in exposed rat pups. Their paper is a preprint awaiting peer review, however. DN’s material does not provide the raw data, a full account of the six allegedly misreported results, or evidence on actual exposure among children near Swedish fields. It cannot establish a human health risk.
ISK Biosciences previously told SVT that the original study had been reviewed by authorities and that it trusted established regulatory processes. That makes EFSA’s review more important: it should produce a clear account of the documented timeline and the treatment of the study. Sweden’s Chemicals Agency is also reviewing fluazinam, with a decision expected in April 2028, DN reports.
Sources
- Dagens Nyheter · Source date: 2026-11-18
Independent editorial content. WUA is not affiliated with any political party. 2026-11-18
Fluazinam: EFSA reopens scrutiny after researchers challenge old study